Xenon pharmaceuticals inc. (XENE)
Income statement / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13
Revenue (note 13):

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue (note 12)

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

-

817

1,214

1,767

4,619

8,500

12,132

15,573

0

0

0

-

-

-

-

-

Collaboration revenue (note 10)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Royalties

-

-

-

-

-

-

-

-

-

-

-

-

36

35

36

0

-

0

0

-

-

0

0

-

0

Revenues

-

-

-

-

-

-

-

-

-

-

-

-

1,803

4,654

8,535

12,168

15,577

25,543

26,547

0

-

0

0

-

0

Operating expenses:
Research and development

38,845

33,495

29,992

27,203

23,634

23,629

24,545

25,238

25,573

23,572

22,373

21,367

19,828

19,695

17,523

16,089

15,152

14,342

13,765

12,662

11,768

10,892

0

0

0

General and administrative

10,803

9,680

8,918

8,789

8,406

8,024

7,830

7,451

7,313

7,085

7,120

6,997

6,792

6,917

6,459

4,961

9,786

9,886

9,881

10,916

5,496

5,521

0

0

0

Buy-out of future milestones and royalties (note 14c)

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

49,648

43,175

44,910

41,992

38,040

37,653

32,375

32,689

32,886

30,657

29,493

28,364

26,620

26,612

23,982

21,050

24,938

23,951

23,369

23,442

17,264

16,690

0

0

0

Loss from operations

-42,819

-39,675

-44,910

-41,992

-38,040

-37,637

-32,095

-32,394

-32,575

-29,986

-28,673

-27,146

-24,817

-21,958

-15,447

-8,882

-9,361

-6,723

2,758

3,937

11,106

17,590

0

0

0

Other income (expense):
Interest income

2,353

2,574

2,371

1,790

1,216

653

452

436

477

550

540

554

504

433

449

489

542

597

605

579

568

533

0

0

0

Interest expense

1,434

1,443

1,758

1,593

1,394

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Foreign exchange gain (loss)

282

-240

-12

-287

-701

-385

245

789

1,394

793

-482

-659

1,316

595

-2,045

-1,466

-6,933

-4,465

-936

-2,027

1,344

64

0

0

0

Gain on termination of collaboration agreement (note 13c)

-

-

-

-

4,398

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss before income taxes

-41,618

-38,784

-44,309

-42,082

-34,521

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax recovery

-23

-7

-20

1

-24

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss and comprehensive loss

-41,595

-38,777

-44,289

-42,083

-34,497

-34,004

-27,363

-26,942

-30,704

-28,643

-28,615

-27,251

-22,997

-20,930

-17,043

-9,859

-15,752

-10,591

2,427

2,489

13,018

18,172

0

0

0

Net loss attributable to preferred shareholders

1,568

1,070

2,355

3,278

2,881

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income attributable to participating securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,258

0

0

0

Net loss attributable to common shareholders

-40,027

-37,707

-41,934

-38,805

-31,616

-31,047

-26,027

-26,909

-30,704

0

0

0

-

-

-

-

-

-

-

-

-

0

0

-

0

Net loss per common share (note 6):
Basic

-

-

-

-0.42

-

-

-

-0.21

-0.45

-0.43

-0.41

-0.42

-0.32

-0.51

-0.42

-0.23

-

-

0.08

-

-

2.67

-

-

0.99

Diluted

-

-

-

-0.42

-

-

-

-0.21

-0.45

-0.43

-0.41

-0.43

-0.32

-0.51

-0.42

-0.23

-

-

-0.07

-

-

1.69

-

-

0.63

Basic and diluted

-

-0.33

-0.37

-

-

-0.63

-0.45

-

-

-

-

-

-

-

-

-

-

-0.27

-

-0.64

-

-

-

-

-

Weighted-average common shares outstanding (note 6):
Basic

-

-

25,773

25,753

-

-

14,306

17,804

17,998

17,998

17,997

17,946

17,902

15,268

14,408

14,394

-

-

14,241

-

-

1,348

1,347

-

1,337

Stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

763

-

-

728

Subscription rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10

-

-

14

Diluted

-

-

25,775

25,753

-

-

14,306

17,804

18,006

18,009

18,015

17,974

17,876

15,268

14,434

14,394

-

-

15,129

-

-

2,122

1,347

-

2,080

Foreign currency translation adjustment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,501

0

0

0

-

Comprehensive income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,517

0

0

0

-

Basic and diluted

-

25,793

-

-

-

20,306

-

-

-

-

-

-

-

-

-

-

-

14,298

-

14,212

-

-

-

1,345

-